Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BCAB 
Bioatla Inc (BCAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/29/2025: BCAB (1-star) is a SELL. SELL since 1 days. Simulated Profits (66.67%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.45% | Avg. Invested days 26 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 43.20M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 4 | Beta 1.02 | 52 Weeks Range 0.24 - 2.52 | Updated Date 10/29/2025 |
52 Weeks Range 0.24 - 2.52 | Updated Date 10/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.1 |
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.2733 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -574.72% |
Management Effectiveness
Return on Assets (TTM) -82.52% | Return on Equity (TTM) -813.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 26752796 | Price to Sales(TTM) 3.93 |
Enterprise Value 26752796 | Price to Sales(TTM) 3.93 | ||
Enterprise Value to Revenue 2.43 | Enterprise Value to EBITDA 0.31 | Shares Outstanding 58721588 | Shares Floating 46161628 |
Shares Outstanding 58721588 | Shares Floating 46161628 | ||
Percent Insiders 10.58 | Percent Institutions 28.62 |
Upturn AI SWOT
Bioatla Inc
Company Overview
History and Background
Bioatla Inc., founded in 2007, is a global biotechnology company focused on developing Conditionally Active Biologics (CABs) antibody therapeutics for cancer. They have evolved through multiple clinical trials and strategic partnerships.
Core Business Areas
- CAB Platform Technology: Development and application of CAB technology to create novel cancer therapies that target the tumor microenvironment more selectively than traditional antibodies.
- Clinical Development: Advancing a pipeline of CAB therapeutic candidates through clinical trials for various solid tumor cancers.
Leadership and Structure
Scott Smith is the Chief Executive Officer. The company has a structured management team with dedicated departments for research, development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- BA3011: CAB-AXL-ADC, an antibody-drug conjugate targeting AXL, is in Phase 2 trials for multiple solid tumors. Competitors include companies developing other AXL-targeted therapies and ADCs. Market share data is not yet fully available as product is in clinical trials, however, AXL is being studied by BMS(BMY) and Merck (MRK).
- BA3021: CAB-ROR2-ADC, an antibody-drug conjugate targeting ROR2, is in Phase 1/2 trials for solid tumors. Competitors include companies developing ROR2 inhibitors and ADCs. Market share data is not yet fully available as product is in clinical trials, however, ROR2 is being studied by AstraZeneca (AZN) and Johnson and Johnson (JNJ).
Market Dynamics
Industry Overview
The biotechnology industry, particularly oncology, is highly competitive and rapidly evolving. There is a high demand for novel cancer therapies with improved efficacy and reduced toxicity.
Positioning
Bioatla is positioned as an innovator in the CAB antibody therapeutic space, aiming to deliver more selective and effective cancer treatments. Competitive advantages include their proprietary CAB platform.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Bioatla's TAM depends on the success of its specific drug candidates and their target indications. Bioatla is positioned to capture a portion of this TAM through successful clinical trials and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary CAB technology platform
- Novel approach to cancer therapy
- Promising preclinical and clinical data
- Experienced management team
Weaknesses
- Dependence on clinical trial outcomes
- High cash burn rate
- Competition from larger pharmaceutical companies
- Relatively small company size
Opportunities
- Potential for strategic partnerships
- Expansion into new therapeutic areas
- Positive clinical trial results leading to regulatory approval
- Increasing demand for targeted cancer therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging therapies
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- MRK
- BMY
- AZN
- JNJ
Competitive Landscape
Bioatla is a smaller player competing with established pharmaceutical giants. Their competitive advantage lies in their novel CAB technology, but they face challenges in terms of resources and market reach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pipeline development and clinical trial advancements. Revenue growth is minimal at this stage.
Future Projections: Future growth depends on the success of clinical trials and potential commercialization of CAB-based therapeutics. Analyst estimates vary based on pipeline progress and market potential.
Recent Initiatives: Recent initiatives include advancing clinical trials for BA3011 and BA3021, exploring new CAB targets, and seeking strategic partnerships.
Summary
Bioatla is an early-stage biotech company with promising CAB technology, but faces significant risks associated with clinical development and competition. Its strengths lie in its innovative approach, while weaknesses include limited resources and dependence on clinical trial outcomes. Positive clinical data and strategic partnerships are crucial for its future success. They need to closely monitor cash flow and navigate the regulatory landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Bioatla Inc. website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bioatla Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-12-16 | Co-Founder, CEO & Chairman Dr. Jay M. Short Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.bioatla.com |
Full time employees 61 | Website https://www.bioatla.com | ||
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.